Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

764 Press Releases
DateTitleCompany
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review EMD Serono and Pfizer,
Published by
PR Newswire
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review Merck and Pfizer,
Published by
PR Newswire
24 Feb 17 Pfizer Prices $1,065,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
23 Feb 17 Ronald E. Blaylock Elected to Pfizer’s Board of Directors Pfizer Inc.,
Published by
Business Wire
21 Feb 17 Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration Pfizer Inc.,
Published by
Business Wire
17 Feb 17 New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a Pfizer Inc.,
Published by
Business Wire
16 Feb 17 Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) Pfizer Inc.,
Published by
Business Wire
27 Jan 17 Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis Pfizer Inc.,
Published by
Business Wire
26 Jan 17 Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection Pfizer Inc.,
Published by
Business Wire
05 Jan 17 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) Pfizer Inc.,
Published by
Business Wire
23 Dec 16 Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca Pfizer Inc.,
Published by
Business Wire
21 Dec 16 FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer Pfizer Inc.,
Published by
Business Wire
19 Dec 16 Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older Pfizer Inc.,
Published by
Business Wire
15 Dec 16 CORRECTING and REPLACING Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema) Pfizer Inc.,
Published by
Business Wire
12 Dec 16 Pfizer Declares First-Quarter 2017 Dividend Pfizer Inc.,
Published by
Business Wire
03 Dec 16 New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Pfizer Inc.,
Published by
Business Wire
01 Dec 16 LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint Pfizer Inc.,
Published by
Business Wire
30 Nov 16 Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab) Pfizer Inc.,
Published by
Business Wire
14 Nov 16 Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers Pfizer Inc.,
Published by
Business Wire
14 Nov 16 Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019 Pfizer Inc.,
Published by
Business Wire
02 Nov 16 Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China Pfizer,
Published by
Business Wire
01 Nov 16 Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor Pfizer Inc.,
Published by
Business Wire
14 Nov 16 CORRECTING and REPLACING Pfizer Announces Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019 Pfizer Inc.,
Published by
Business Wire
16 Nov 16 National Advisory Committee on Immunization (NACI) gives Prevnar® 13 Grade A recommendation Pfizer Canada Inc.,
Published by
PR Newswire
13 Nov 16 Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen Pfizer,
Published by
Business Wire
15 Nov 16 Pfizer Prices $6,000,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
11 Nov 16 Pfizer Announces Major Expansion of Humanitarian Assistance Program Pfizer Inc.,
Published by
Business Wire
21 Nov 16 Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire Pfizer Inc.,
Published by
Business Wire
21 Nov 16 Pfizer Announces Expiration And Results Of Tender Offer For Any And All Of Its 6.200% Senior Notes Due March 15, 2019 Pfizer Inc.,
Published by
Business Wire
18 Nov 16 Pfizer Announces Pricing of Tender Offer for Any and All of its 6.200% Senior Notes Due March 15, 2019 Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.